Table 1.
Efficacy studies.
| Regimen | Enrolled subjects |
Sperm concentration threshold (million/ml) |
Subjects reaching threshold | Subjects entering efficacy |
Subjects completing efficacy | Pregnancy rate N (%/couple-year) |
|---|---|---|---|---|---|---|
| TE 200 mg/week7 | 271 | azoospermia | 157 | 157 | 119 | 1 (0.8) |
| TE 200 mg/week8 | 399 | < 3 (reduced from < 5) | 349 | 268 | 209 | 4 (1.4) |
| TU 1000 (loading) + 500 mg/4 week9 | 308 | < 3 | 299 | 296 | 280 | 1 (2.3)* |
| Depot MPA 300 mg/12 week testosterone pellets 800 mg/24–16 week10 |
55 | < 1 | 53 | 51 | 30 | 0 (0) |
| TU 1000 (loading) + 500 mg/4 week11 | 1045 | ⩽ 1 | 855 | 855 | 733 | 9 (1.1) |
| TU 1000 mg + NETE 200 mg/8 week12 | 320 | ⩽ 1 | 274 | 266 | 111$ | 4 (1.57) |
*
One pregnancy was attributed to sperm rebound.
$
Trial terminated before the planned end of the study.
MPA, medroxyprogesterone acetate; NETE, norethisterone enanthate; TE, testosterone enanthate; TU, testosterone undecanoate.